Skip to content
Back to the daily read

Daily Read: Business

Novo Nordisk CEO Eyes M&A to Bolster Weight‑Loss Portfolio

Novo Nordisk CEO Mike Doustdar told CNBC that the company is exploring mergers and acquisitions to strengthen its drug pipeline amid growing competition in the weight‑loss market. Doustdar said the firm is looking for gaps where other companies have developed or are about to launch drugs that Novo cannot produce quickly enough. He added that the company would consider acquiring such assets if they could fill those gaps and help Novo stay ahead in a crowded field. The comments came during a CNBC “Squawk Box Europe” interview in New York on Tuesday, following the launch of Novo’s Wegovy and the rise of competitors like Eli Lilly’s Mounjaro. Novo’s strategy reflects a broader trend in the pharmaceutical industry, where firms seek acquisitions to accelerate product development and broaden their portfolios. Doustdar did not disclose any specific targets or deal terms, but indicated that the company is actively evaluating opportunities. The announcement may signal a shift in Novo’s growth plans as it seeks to maintain its leadership in obesity treatment.

· CNBC

The essential points

  1. 01Novo Nordisk CEO Mike Doustdar signals intent to pursue M&A to close gaps in its weight‑loss drug pipeline.
  2. 02Company is targeting acquisitions that offer drugs Novo cannot develop quickly enough to stay competitive.
  3. 03The remarks were made during a CNBC “Squawk Box Europe” interview in New York on Tuesday.
  4. 04No specific targets or deal terms were disclosed, but Novo is actively evaluating opportunities.
The full brief

Novo Nordisk CEO Mike Doustdar told CNBC that the company is exploring mergers and acquisitions to strengthen its drug pipeline amid growing competition in the weight‑loss market. Doustdar said the firm is looking for gaps where other companies have developed or are about to launch drugs that Novo cannot produce quickly enough. He added that the company would consider acquiring such assets if they could fill those gaps and help Novo stay ahead in a crowded field.

The comments came during a CNBC “Squawk Box Europe” interview in New York on Tuesday, following the launch of Novo’s Wegovy and the rise of competitors like Eli Lilly’s Mounjaro. Novo’s strategy reflects a broader trend in the pharmaceutical industry, where firms seek acquisitions to accelerate product development and broaden their portfolios. Doustdar did not disclose any specific targets or deal terms, but indicated that the company is actively evaluating opportunities.

The announcement may signal a shift in Novo’s growth plans as it seeks to maintain its leadership in obesity treatment.